Arch Therapeutics, Inc (OTCQB:ARTH) Revenue and Competitors

Claim your profile

Location

$20.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Arch Therapeutics, Inc (OTCQB:ARTH)'s estimated annual revenue is currently $1.7M per year.(i)
  • Arch Therapeutics, Inc (OTCQB:ARTH)'s estimated revenue per employee is $155,000
  • Arch Therapeutics, Inc (OTCQB:ARTH)'s total funding is $20.9M.

Employee Data

  • Arch Therapeutics, Inc (OTCQB:ARTH) has 11 Employees.(i)
  • Arch Therapeutics, Inc (OTCQB:ARTH) grew their employee count by 57% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Arch Therapeutics, Inc. (OTCQB:ARTH) is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5® Advanced Wound System and AC5® Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G™, AC5-V® and AC5® Surgical Hemostat, among others.1,2 1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use. 2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.

keywords:N/A

$20.9M

Total Funding

11

Number of Employees

$1.7M

Revenue (est)

57%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Arch Therapeutics, Inc (OTCQB:ARTH) News

2022-04-13 - Renowned Wound Care Key Opinion Leaders Presented Arch ...

FRAMINGHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and...

2022-03-30 - Arch Therapeutics' AC5® Advanced Wound System to be ...

(OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced...

2022-03-22 - Arch Therapeutics Partners with Centurion Therapeutics to ...

FRAMINGHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.8M12N/AN/A
#2
$3M12N/AN/A
#3
$2M14N/AN/A
#4
$1.3M15N/AN/A
#5
$2.2M1623%N/A